Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is in a strong financial position with a solid market share and potential for growth through strategic M&A. With a focus on providing high-quality services to residents of LTCFs and a strong customer experience, the company is well-positioned for continued success. Regulatory changes in the industry also provide potential for further growth and expansion.

Bears say

Guardian Pharmacy Service is poised to experience strong organic growth due to an aging baby boomer population and its three-pronged growth strategy focused on increasing adoption rates, adding new accounts, and expanding into neighboring markets. However, its operations may face challenges with reimbursement and regulatory uncertainty, as well as the potential impact of Medicare's new drug pricing regulations in 2026. Additionally, the company's local autonomy model and strong employee benefits may differentiate it from competitors, but there is opportunity for margin improvement through shared systems and AI implementation. Overall, the company presents both growth potential and challenges, warranting a cautious outlook from a financial analyst.

GRDN has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 6 analysts, GRDN has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.